Open Access

Tuberculosis treatment adherence and fatality in Spain

Respiratory Research200910:121

https://doi.org/10.1186/1465-9921-10-121

Received: 8 July 2009

Accepted: 1 December 2009

Published: 1 December 2009

Abstract

Background

The adherence to long tuberculosis (TB) treatment is a key factor in TB control programs. Always some patients abandon the treatment or die. The objective of this study is to identify factors associated with defaulting from or dying during antituberculosis treatment.

Methods

Prospective study of a large cohort of TB cases diagnosed during 2006-2007 by 61 members of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Predictive factors of completion outcome (cured plus completed treatment vs. defaulters plus lost to follow-up) and fatality (died vs. the rest of patients) were based on logistic regression, calculating odds ratios (OR) and 95% confidence intervals (CI).

Results

Of the 1490 patients included, 29.7% were foreign-born. The treatment outcomes were: cured 792 (53.2%), completed treatment 540 (36.2%), failure 2 (0.1%), transfer-out 33 (2.2%), default 27 (1.8%), death 27 (1.8%), lost to follow-up 65 (4.4%), other 4 (0.3%). Completion outcome reached 93.5% and poor adherence was associated with: being an immigrant (OR = 2.03; CI:1.06-3.88), living alone (OR = 2.35; CI:1.05-5.26), residents of confined institutions (OR = 4.79; CI:1.74-13.14), previous treatment (OR = 2.93; CI:1.44-5.98), being an injecting drug user (IDU) (OR = 9.51; CI:2.70-33.47) and treatment comprehension difficulties (OR = 2.93; CI:1.44-5.98). Case fatality was 1.8% and it was associated with the following variables: age 50 or over (OR = 10.88; CI:1.12-105.01), retired (OR = 12.26;CI:1.74-86.04), HIV-infected (OR = 9.93; CI:1.48-66.34), comprehension difficulties (OR = 4.07; CI:1.24-13.29), IDU (OR = 23.59; CI:2.46-225.99) and Directly Observed Therapy (DOT) (OR = 3.54; CI:1.07-11.77).

Conclusion

Immigrants, those living alone, residents of confined institutions, patients treated previously, those with treatment comprehension difficulties, and IDU patients have poor adherence and should be targeted for DOT. To reduce fatality rates, stricter monitoring is required for patients who are retired, HIV-infected, IDU, and those with treatment comprehension difficulties.

Introduction

Tuberculosis (TB) is an infectious disease requiring adherence to long-term treatment and the tracing of patient's contacts, thus justifying it being a notifiable disease in most countries of the world. This ancient disease continues to be an important public health problem, and for this reason the World Health Organisation (WHO) declared it to be a global emergency in 1993 [1]. In 2007 it was estimated that, worldwide, there had been 9.27 million new cases and 1.756 million deaths from TB, of which 1.37 million cases and 0.456 million deaths were among HIV-infected individuals[2]. Moreover, to these new cases one must add the millions already in existence, making it the most prevalent infectious disease[3].

The rise of immigration over the last decade in Spain has substantially altered the characteristics of TB patients. The Spanish population was 45,200,737 inhabitants in 2007, of whom 4,419,554 (9.99%) were foreign-born[4]. In Barcelona, a city with one of the highest influxes of immigrants, the percentage of foreign-born TB patients rose from 5% in 1995 to 46% in 2007 (with incidence rates among immigrants of over 100 cases per 100,000 inhabitants) [5].

The Tuberculosis and Respiratory Infections section of SEPAR (Spanish Society of Pneumology and Thoracic Surgery) has previously published a study on adherence to anti-tuberculosis treatment and on fatality, referring to a cohort of patients followed during the period 1999 to 2000[6]. The findings indicated that immigrant status and being an injecting drug user were associated with worse treatment adherence, while patients who were HIV-infected, alcoholics, or of advanced age presented higher fatality.

The aims of the present study were to analyse antituberculosis treatment adherence and fatality during standard TB treatments in patients with TB in Spain, and to identify factors associated with these events. The study will also permit changes in relation to the earlier study[6] to be assessed, and to determine whether demographic changes experienced in Spain due to the considerable rise in immigration have had any influence on adherence to tuberculosis treatment.

Methods

A multicentric prospective study was carried out involving prospective follow-up of an extensive cohort of TB patients, provided by 61 collaborators from 53 hospitals throughout Spain. The study was promoted by the Integrated TB Research Programme of SEPAR. Patients diagnosed with TB between 1 January 2006 and 31 December 2007, aged 18 years or over, were included. Those patients with known resistances were excluded, as were those in whom initiation of standard TB treatment was not advisable, such as patients with hepatic problems. Cases were followed up according to an evaluation calendar (Table 1). An informed consent to participate in the study was elicited.
Table 1

Patient evaluation calendar

 

Visit 1

Diagnosis

Visit 2

2 Months

Visit 3 *

6 Months

Criteria of inclusion/exclusion

X

  

Sociodemographic data

X

  

Tobacco, alcohol, drug use

X

  

Anthropometric data

X

X

X

Clinical history

X

  

Diagnostic method employed

X

  

Medication

X

X

X

Clinical course

 

X

X

Adherence to treatment

 

X

X

Collection of samples

X

X

X

Drug sensitivity test

X

  

Treatment outcome

  

X

Informed consent

X

  

* For long treatments new visits are recommended at 9,12,18 months.

The information collected covered the following aspects: sociodemographic data, toxic habits, clinical history, diagnostic methods, drug-susceptibility, medication, clinical course, and adherence to and outcome of treatment. Data was collected through an electronic diary made available through a computerised application, accessed by each study collaborator via the SEPAR Web site using a personalised username and password.

Any patient born outside Spain was classified as an immigrant. Men consuming over 280 g of alcohol per week, and women over 168 g, were considered alcoholics. Intravenous users of illegal drugs (heroin and cocaine) were classified as intravenous drug users (IVDU). Toxicity was defined as an adverse effect that requires to change at least one drug, and treatment comprehension was defined as the perception of the treating doctors of the patient. The chest X-Rays were performed at the moment of the diagnosis and at the 2nd and 6th month and when necessary, and the evolution was classified by the treating doctor of the patient as improvement, stable or progression.

During these years the standard treatment for TB in Spain for new cases were: 2 months of rifampicin (R), isoniazid (H) and pirazinamide (Z) followed by 4 months of RH (2RHZ+4RH) or the same treatment plus Ethambutol (E) during the first 2 months20 (2RHZE+4RH). In Spain DOTS is a priority only for patients with high risk of bad adherence (IVDU, homeless, prisoners, etc). A patient was included in the previous treatment category only if he or she had taken antituberculosis treatment over one year before the current active TB episode.

Control of questionnaire completion and the database was carried out via telephone and e-mail contacts between the field worker and study collaborators.

The following definitions were employed for treatment outcome, in accordance with European recommendations[7]:

Cured: when the patient has completed a full course of anti-TB therapy and a negative culture is obtained during the continuation phase (culture-positive patients) or two negative sputum smears during the continuation phase, one of which must be at the end of treatment (patients diagnosed by microscopy).

Treatment completed: if the course of treatment prescribed was completed but no bacteriological conversion occurred (culture-positive patients) or no smear result is available at the end of treatment (patients diagnosed by microscopy).

Default: If the patient interrupts the treatment for any reason for more than two months, if there is a non-completion of treatment within 9 months when the patient is placed on a six-month regimen, or if the drug intake was < 80% of the prescribed dose.

Treatment failure: A patient who fails to achieve bacteriological conversion within 5 months after the start of treatment or, after previous conversion, becomes sputum smear or culture positive again.

Death: A patient who died of any cause during the course of treatment is recorded under death.

In the present study, the category of transfer out[7] was redefined into two subcategories:

Lost to follow-up: when it is known that the patient disappeared and no additional information is available.

Transfer out: when a patient moves to another town or health centre and whose follow-up (with medical report available) is the responsibility of a doctor not collaborating in the present study.

The results of the analysis were summarized as:

Successful outcome: the percentage of patients who were cured or completed treatment out of all those detected.

Completion outcome: the percentage of patients who were cured or completed treatment out of all patients who were cured or completed treatment, were defaulters, or were lost to follow up.

Case-fatality rate: the percentage of patients who died during TB treatment out of all patients who were cured or completed treatment or were defaulters.

Potentially unsatisfactory outcome: the percentage of patients who interrupted treatment, were lost to follow up, or failed treatment out of all detected patients.

In accordance with guidelines of the Council for International Organizations of Medical Sciences (CIOMS, Geneva, 1991), and with recommendations of the Spanish Epidemiology Association regarding review of ethical aspects of epidemiological studies, the present study was submitted for evaluation to the Research Ethical Committee of the Teknon Medical Center, Barcelona and was approved on February 24th, 2006. All records with patients were identified were confidential and handled in accordance with the Spanish Data Protection Law 15/December13th, 1999 (Protección de Datos de Carácter Personal). Principles of the Helsinki Declaration were followed at all times. Each patient had an informed consent card read aloud to them.

Statistical analysis

A descriptive study was carried out of the qualitative and quantitative variables collected in order to characterise the study population. Frequency distributions and medians for quantitative variables were calculated. Proportions were compared between groups using χ2 tests, and when pertinent, the two-sided Fisher test. Quantitative variables were compared using Student's t-test or its non-parametric equivalent, the Mann-Whitney U-test, when assumptions of normality and homogeneity of variances were not met. Measures of association were calculated using odds ratios (OR) along with their 95% confidence intervals (CI). The analysis of factors associated with poor adherence treatment defaulting (comparing: cured plus treatment completed vs. defaulters plus lost to follow-up) and of fatality (comparing: died vs. the rest of patients) were analysed using logistic regression (stepwise method) including in the model the variables associated at the univariate level with a p-value < 0.15. A p-value of under 0.05 was considered significant. The test of Hosmer and Lemeshow was used to check the goodness-of-fit of the models. Analyses were conducted using the SPSS statistical package, version 13.0 (SPSS Inc, Chicago, IL, USA).

Results

The number of patients included initially was 1500, however 10 (0.6%) had to be excluded for not meeting any inclusion criteria, so the final number of patients analysed was 1490 (table 2). The majority were males, aged >31 years old, native, occupationally active, lived with their families, diagnosed via emergency services, had pulmonary TB, either smokers or ex-smokers, initially treated with three drugs, and who understood well the implications of having TB and its treatment. They were also characterised by low frequencies of HIV infection, IDU, alcoholism, previous TB treatment, low levels of drug resistances, toxicities to drugs, and of treatment via DOT. Table 2 presents the final outcomes of therapy, where it may be noted that 89.4% of cases were cured or completed treatment. It is estimated that 1.8% defaulted, and 4.4% of cases were lost to follow-up and probably did not complete treatment.
Table 2

Distribution of patients in terms of study variables.

Variables

 

N (%)

SEX

Men

920 (63.4)

 

Women

532 (36.6)

COUNTRY

Immigrant

442(29.7)

 

Native

1048(70.3)

AGE

18-30

497 (33.4)

 

31-50

596 (40.0)

 

>50

397 (26.6)

OCCUPATIONAL STATUS

Active

901 (60.5)

 

Disabled

68 (4.5)

 

Unemployed

257 (17.2)

 

Retired

220 (14.8)

 

Unknown

44 (3.0)

LIVING ARRANGEMENTS

Alone

157 (10.5)

 

Confined institutions

54 (3.6)

 

Shared accommodation

189 (12.7)

 

Family

1062 (71.3)

 

Unknown

28 (1.9)

SOURCE

Hospital emergency department

682 (45.8)

 

Primary Health Care

268 (18.0)

 

Specialist

210 (14.1)

 

Unknown

330 (22.1)

HIV-infected

No

1060 (71.2)

 

Yes

66 (4.4)

 

Unknown

364 (24.4)

INTRAVENOUS DRUG USERS

No

872 (58.5)

 

Yes

21 (1.4)

 

Unknown

597 (40.1)

LOCALIZATION

Pulmonary

1249 (83.8)

 

Extrapulmonary

159 (10.7)

 

Mixed

67 (4.5)

 

Unknown

15 (1.0)

ALCOHOL USE

No

1064 (71.4)

 

Yes

375 (25.2)

 

Unknown

51 (3.4)

SMOKING

Non-smoker

676 (45.4)

 

Smoker or ex smoker

797 (53.5)

 

Unknown

17 (1.1)

INITIAL THERAPY

3 Drugs

770 (51.7)

 

4 Drugs

649 (43.5)

 

Unknown

71 (4.8)

DRUG RESISTANCE*

No

864 (80.1)

 

Yes

85 (7.9)

 

Unknown

129 (12.0)

TOXICITY

Yes

74 (5.0)

 

No

1416 (95.0)

PREVIOUS TREATMENT

Yes

131 (9.0)

 

No

1320 (91.0)

DIRECTLY OBSERVED TREATMENT

No

1338 (89.8)

 

Yes

152 (10.2)

TREATMENT COMPREHENSION

Easy

1266 (85.0)

 

Difficult

139 (9.3)

 

Unknown

85 (5.7)

FINAL OUTCOME

Cured

792 (53.2)

 

Completed treatment

540 (36.2)

 

Failure

2 (0.1)

 

Transfer out

33 (2.2)

 

Default

27 (1.8)

 

Death

27 (1.8)

 

Lost to follow up

65 (4.4)

 

Other

4 (0.3)

*Only patients with positive culture

According to these data, the outcome was 'successful' in 89.4% of patients considering all cases and 83.1% considering only smear-positive cases. Completion was 93.5% considering all TB cases and 92.4% considering only smear-positive cases. Among the immigrants, these percentages were 87.8 and 88.3, respectively. The outcome of 'potentially unsatisfactory' accounted for 6.3% of all cases and 7.4% for smear-positive cases.

The analysis of factors possibly associated to poor adherence are presented in table 3. As presented in the table, at the univariate level poorer adherence was observed for men, immigrants, younger patients, those not retired, those not living with their family, HIV-infected patients, previously treated subjects, those who had difficulty understanding the treatment, those diagnosed via emergency services, and IDU patients, whereas being in DOT had no influence. Multivariate analysis confirmed the influence of being an immigrant, living alone, being residents of confined institutions, previous TB treatment, having difficulty understanding the treatment, and being IDU.
Table 3

Analysis of factors associated with poor adherence to antituberculosis treatment.

   

UNIVARIATE ANALYSIS (p ≤ 0.05)

MULTIVARIATE ANALYSIS (p ≤ 0.05)

Variables

 

N (%defaulters)

p-value

OR

95%CI

p-value

OR

95%CI

SEX

Men

880 (7.5)

0.015

1.87

1.13 - 3.09

   
 

Women

506 (4.2)

 

1

    

COUNTRY

Immigrant

420 (12.1)

< 0.001

3.24

2.11 - 4.98

0.031

2.03

1.06 - 3.88

 

Native

1004 (4.1)

 

1

  

1

 

AGE

18-30

479 (8.1)

0.019

2.08

1.12 - 3.83

   
 

31-50

578 (6.6)

0.109

1.65

0.89 - 3.04

   
 

> 50

367 (4.1)

 

1

    

OCCUPATIONAL STATUS

Active

876 (6.1)

0.028

3.17

1.13 - 8.86

   
 

Disabled

61 (8.2)

0.031

4.39

1.14 - 16.92

   
 

Unemployed

244 (11.1)

0.001

6.12

2.10 - 17.82

   
 

Retired

201 (2.0)

 

1

    

LIVING ARRANGEMENTS

Alone

145 (10.3)

< 0.001

3.27

1.74 - 6.16

0.037

2.35

1.05 - 5.26

 

Confined institutions

45 (24.4)

< 0.001

9.18

4.30 - 19.62

0.002

4.79

1.74 - 13.14

 

Sharing accom.

180 (12.2)

< 0.001

3.95

2.26 - 6.91

0,263

1,59

0,70-3,62

 

Family

1029 (3.4)

 

1

  

1

 

HIV-infected

Yes

60 (13.3)

0.029

2.40

1.09 - 5.29

   
 

Unknown

349 (6.6)

0.697

1.10

0.67 - 1.81

   
 

No

1015 (6.0)

 

1

    

PREVIOUS TREATMENT COMPREHENSION

Yes

121 (17.4)

< 0.001

3.75

2.20 - 6.30

0.009

2.80

1.29 - 6.08

 

No

1264 (5.3)

 

1

  

1

 
 

Difficult

122 (11.5)

0.001

3.60

1.91 - 6.79

0.003

2.93

1.44 - 5.98

 

Easy

1238 (3.5)

 

1

  

1

 

SOURCE

Emergencies

646 (9.0)

0.006

2.76

1.34 - 5.66

   
 

Primary Care

261 (3.4)

 

1

    
 

Specialist

203 (4.4)

0.587

1.29

0.50 - 3.33

   
 

Other

314 (5.1)

0.338

1.50

0.65 - 3.46

   

INTRAVENOUS DRUG USERS

No

830 (4.5)

 

1

  

1

 
 

Yes

19 (21.1)

0.003

5.71

1.80 - 18.07

0.001

9.51

2.70 - 33.47

 

Unknown

575 (8.9)

0.001

2.08

1.34 - 3.23

0.027

2.00

1.08 - 3.72

DIRECTLY OBSERVED TREATMENT

Yes

140 (7.1)

0.730

1.12

0.57 - 2.22

   
 

No

1284 (6.4)

 

1

    

Also had no influence at univariate level: resistance, alcohol, smoking, radiology, and localization.

CI: Confidence Interval

OR: Odds ratio

The case-fatality was 1.8%. The analysis of factors associated with fatality is presented in table 4. Variables having an influence at the univariate level were: immigrant, disabled or retired, residents of confined institutions or incarcerated, HIV-infected, IDU, no radiological improvement, and being in DOT. Multivariate analysis confirmed the influence of being aged over 50, being retired, being HIV-infected, having comprehension difficulties, being IDU, and having been treated under DOT.
Table 4

Analysis of factors associated with dying during the expected treatment period among patients with tuberculosis.

   

UNIVARIATE ANALYSIS (p ≤ 0.05)

MULTIVARIATE ANALYSIS (p ≤ 0.05)

Variables

 

N (%deaths)

p-value

OR

95%CI

p-value

OR

95%CI

AGE

18-30

497 (0.2)

 

1

    
 

31-50

596 (0.8)

0.191

4.19

0.48 - 36.03

   
 

> 50

397 (5.3)

0.001

27.70

3.71 - 206.86

0.039

10.88

1.12 - 105.01

SEX

Men

920 (1.8)

0.965

0.98

0.44 - 2.16

   
 

Women

532 (1.9)

 

1

    

COUNTRY

Immigrant

442 (0.9)

0.099

0.40

0.14 - 1.18

   
 

Native

1048 (2.2)

 

1

    

OCCUPATIONAL STATUS

Active

901 (0.4)

 

1

    
 

Disabled

68 (5.9)

< 0.001

14.01

3.42 - 57.34

   
 

Unemployed

257 (0.8)

0.516

1.75

0.32 - 9.65

   
 

Retired

220 (6.8)

< 0.001

16.40

5.39 - 49.95

0.012

12.26

1.74 - 86.04

LIVING ARRANGEMENTS

Alone

157 (2.5)

0.399

1.60

0.53 - 4.83

   
 

Confined institutions

54 (5.6)

0.045

3.61

1.02 - 12.73

   
 

Sharing accom.

189 (0.5)

0.279

0.32

0.04 - 2.47

   
 

Family

1062 (1.6)

 

1

    

HIV-INFECTED

Yes

66 (7.6)

0.001

5.71

2.00 - 16.22

0.018

9.93

1.48 - 66.34

 

Unknown

364 (1.9)

0.499

1.36

0.55 - 3.37

   
 

No

1060 (1.4)

 

1

    

PREVIOUS TREATMENT

Yes

131 (3.8)

0.092

2.34

0.87 - 6.28

   
 

No

1320 (1.7)

 

1

    

COMPREHENSION

Difficult

139 (5.0)

< 0.001

7.40

2.71 - 20.21

0.020

4.07

1.24 - 13.29

 

Easy

1266 (0.7)

 

1

    

ALCOHOL USE

Yes

375 (2.4)

 

1

    
 

No

1064 (1.5)

0.258

0.621

    
     

0.27 - 1.41

   

INTRAVENOUS DRUG USERS

No

872 (2.2)

      
 

Yes

21 (9.5)

0.046

4.72

1.02 - 21.74

0.006

23.59

2.46 - 225.99

 

Unknown

597 (1.0)

 

1

    

RADIOLOGICAL EVOLUTION

Improvement

982 (0.6)

 

1

    
 

Stable/progression

294 (3.1)

0.002

5.13

1.81 - 14.55

   
 

Unknown

214 (5.6)

< 0.001

9.66

3.58 - 26.04

   

DIRECTLY OBSERVED TREATMENT

Yes

152 (3.9)

0.044

2.57

1.02 - 6.48

0.038

3.54

1.07 - 11.77

 

No

1338 (1.6)

 

1

    

Also had no influence at univariate level: resistance, smoking, and localization.

CI: Confidence Interval

OR: Odds ratio

Discussion

In the present study, the completion outcome was 93.5% and the treatment success outcome was 89.4%, better percentages than observed in the previous study conducted by our group [6]. A study in England, Wales and Northern Ireland found a treatment success of 79% when calculated for cases in which outcome information was reported and 62% for all cases[8]. The treatment completion outcome published by the Barcelona Tuberculosis Control Program was 95.9%[9]. However, according to several studies, antituberculosis therapy adherence percentages are variable: USA[10] (91.2%); San Francisco[11] (88.6%); Norway[12] (83%); Europe[13] (69%) although the way in which theses percentages are calculated could have some influence.

In our opinion, completion outcome is a better indicator of adherence than successful outcome because is not influenced by the number of deaths (sometimes related to old patients or co morbidities but not to the quality of the Program). It is therefore essential to unify definition criteria: even though there is agreement over how to calculate the successful outcome, different methodologies are employed in calculating completion, making comparisons difficult. We consider that the ideal formula for calculating completion outcomes is that used in the present study (percentage of patients who were cured or completed treatment out of all patients who were cured or completed treatment, were defaulters, or were lost to follow-up). Furthermore, we believe it would be important to add the category 'lost to follow-up' to the European definition when it is known that the patient disappeared and no additional information is available, only considering as 'transfer out' a patient who moves to another town or changes to another health centre and whose follow-up is performed by some other physician not collaborating in the study.

Several risk factors of poor adherence have already been identified in other studies (residents of confined institutions, incarcerated, IDU, previous antituberculosis treatment, HIV-infected and immigrant) [8, 14]. In our earlier study[6], the variables found to be associated were IDU and immigration while sex, age, and residents of confined institutions, incarceration, DOT or hospitalisation were not associated. In the present study, IDU and immigrant status continue to be associated, and we have also detected the influence of living alone, being residents of confined institutions, having difficulty understanding the treatment, and having previously undergone antiTB treatment. Sex, age group, occupational status, HIV status and having been diagnosed via emergency department had no influence. It is worth stressing the importance of not living with a family and the initial assessment made by the clinician in relation to the ease with which the patient comprehends the treatment. Many of those having difficulty understanding the treatment were immigrants, although some were native patients.

The case-fatality rate is low compared with other studies[15] due to the fact that in our study one of the criteria for exclusion was non-applicability of standard treatment for whatever reason (known resistances, various types of co morbidity), and also due to the fact that the frequency of HIV-infected patients with neoplasms or of advanced age was relatively low. In an European study, it was observed that advancing age and resistance to isoniazid and rifampicin were the strongest determinants of death, while male sex, European origin, pulmonary site of disease and previous anti-TB treatment were weaker predictors[16]. In an inner-city cohort, underlying illnesses such as diabetes mellitus, renal failure, chronic obstructive pulmonary disease, and HIV infection were predictors of death[17]. In Mexico, predictors of death included delays in treatment after onset of the disease and low adherence of patients to the treatment regime[18].

In our first study, the variables found to be predictive of fatality were alcoholism, HIV infection and age >64 years, whereas sex, IDU, residents of confined institutions, DOT and hospitalisation were not. In the present study, the influence of HIV and of retirement (a "proxy" of older age) is confirmed, and in addition we identify being aged over 50, being IDU, difficulties in comprehending the treatment, and being treated under DOT. In contrast, sex, immigrant status, sharing accommodation, previous antituberculosis treatment, radiological evolution, and alcoholism had no influence. When the two studies are compared, the distribution by sex, age-group and other variables are fairly similar, but the percentage of immigrants now is steadily increasing, as in other countries of Europe[19]. In relation to DOT, in the current study only 9.3% of patients were under this treatment, and in general doctors prioritise DOT for more complicated patients. In any case, it should be emphasised from analysing the predictor variables in the present study that the variable of understanding the treatment is very important not only for adherence, but also for fatality. Therefore, patients in whom the clinician observes this difficulty should be candidates for DOT and for closer monitoring in general.

In regard to the type of therapy applied, it was observed that, in line with Spanish recommendations during these years and given the low rates of primary resistance to isoniazid, the majority of native patients had received treatment with three drugs (fixed dose combinations of rifampicin, isoniazid and pyrazinamide) whereas foreign-born patients (with a higher proportion of resistance to isoniazid) were recommended to take four drugs[20], i.e. adding ethambutol. It has recently been observed that there is a progressive rise in resistances[21, 22] and that this is particularly the case in the immigrant population, and hence the use of four drugs has been recommended in the treatment of incident TB patients[23], in line with both USA[24] and UK[25] guidelines.

It should be noted that the present study was carried out by a scientific society of pneumologists, and that a considerable number of collaborators contributed an extensive cohort of patients. Follow-up of cases was exhaustive, although they cannot be extrapolated to all TB patients in Spain since the study involved physicians particularly motivated by this disease. It is therefore possible that percentages of defaulting and of fatality among TB cases in Spain would be somewhat higher in general. Another limitation of this study is that patients with TB drug resistance were not included because they can have prior history of abandonment of TB treatments.

In summary, the percentage of cases coming from foreign countries is greater than recorded previously[6]. Being an immigrant, living alone, being residents of confined institutions, having a history of antiTB treatment, having difficulty in understanding the treatment, and being IDU are all factors associated with poor adherence. Death was associated with patients who were: over the age of 50, retired, HIV-infected, IDU, having difficulty understanding treatment, and being treated according to DOT (explainable since it is applied above all in the most difficult patients[26]). Therefore, to improve adherence, special care should be taken to treat patients with social problems (DOT at home, methadone programs even in prisons, admission to TB DOT centres) [27]. To reduce fatality, earlier suspicion, diagnosis, and treatment are necessary, particularly among the elderly and those patients with comorbidity or immunodepression. Community health worker intervention[28] and closer monitoring is necessary for patients in whom the physician perceives any difficulty in understanding the treatment (whether immigrants or native); this would lead not only to improved adherence, but also to better survival among these TB patients.

Conclusion

It is important that every city, region or country studies adherence to TB treatment and its predictive factors. In our case, this study was performed by a national scientific society of pneumology and these results can help to improve the control of TB patients in our country, and in others.

Declarations

Acknowledgements

Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE):

R. Agüero (H Marqués de Valdecilla, Santander); J.L. Alcázar (Instituto Nacional de Silicosis, Oviedo); L. Altube (H Galdakao, Galdakao); L. Anibarro (Unidad de Tuberculosis de Pontevedra, Vigo); M. Barrón (H San Millán-San Pedro, Logroño); S. Benoliel (H 12 de Octubre, Madrid); L. Borderías (H San Jorge, Huesca); A. Bustamante (H Sierrallana, Torrelavega); J.L. Calpe (H La Marina Baixa, Villajoyosa); E. Cases (H Universitario La Fe, Valencia); R. Castrodeza (H El Bierzo Ponferrada-León, Ponferrada); J.J. Cebrián (H Costa del Sol, Marbella); J. E. Ciruelos (Hospital de Cruces, Guetxo); M.L. De Souza (Unidad Prevención y Control Tuberculosis, Barcelona); D. Díaz (Complejo Hospitalario Juan Canalejo, La Coruña); B. Fernández (H de Navarra, Pamplona); A. Fernández (H Río Carrión, Palencia); J. Gallardo (H General de Guadalajara, Guadalajara); M. Gallego (Corporación Sanitaria Parc Taulí, Sabadell); C. García (H General Isla Fuerteventura, Puerto del Rosario); F.J. García (H Universitario de la Princesa, Madrid); J.A. Gullón (Hospital Universitario de Canarias, La Laguna); M. Iglesias (H Marqués de Valdecilla, Santander); M.A. Jiménez (Unidad Prevención y Control Tuberculosis, Barcelona); J.M. Kindelan (H Universitario Reina Sofía, Córdoba); J. Laparra (H Donostia-San Sebastián, San Sebastián); T. Lloret (H General Universitario de Valencia, Valencia); M. Marín (H General de Castellón, Castellón); J.T. Martínez (H Mutua de Terrasa, Tarrasa); E. Martínez (H de Sagunto, Sagunto); A. Martínez (H de La Marina Baixa, Villajoyosa); J.F. Medina (H Universitario Virgen del Rocío, Sevilla); C. Melero (H 12 de Octubre, Madrid); C. Milà (Unidad Prevención y Control Tuberculosis, Barcelona); I. Mir (H Son Llatzer, Palma de Mallorca); M.A. Morales (Hospital Cruz Roja Inglesa, Ceuta); V. Moreno (H Carlos III, Madrid); L. Muñoz (H Reina Sofía, Córdoba); C. Muñoz (H Clínico Universitario de Valencia, Valencia); J.A. Muñoz-Calero (H Universitario Central, Oviedo); I. Parra (H Universitario Virgen de la Arrixaca, El Palmar); T. Pascual (H de Cabueñes, Gijón); A. Penas (Complejo Hospitalario Xeral-Calde, Lugo); J.A. Pérez (H Arnau de Vilanova, Valencia); P. Rivas (H Virgen Blanca, León); J. Sala (H Universitario Joan XXIII, Tarragona); M. Sánchez (Unidad Tuberculosis Distrito Poniente, Almería); P. Sánchez (H del Mar, Barcelona); E. Trujillo (Complejo Hospitalario de Ávila, Ávila); E. Valencia (H Carlos III, Madrid); A. Vargas (H Universitario Puerto Real, Cádiz); I. Vidal (Complejo Hospitalario Juan Canalejo, La Coruña); M. Vizcaya (Complejo Hospitalario Universitario de Albacete, Albacete); M. Zabaleta (H de Laredo, Laredo); G. Zubillaga (H Donostia-San Sebastián, San Sebastián).

Authors’ Affiliations

(1)
Programa Integrado de Investigación en Tuberculosis (PII TB) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
(2)
Unidad de Investigación de Tuberculosis de Barcelona, Servicio de Epidemiología de la Agencia de Salud Pública de Barcelona
(3)
Fundación Respira de la SEPAR
(4)
Hospital Universitario Germans Trías y Pujol de Badalona
(5)
Hospital General Universitario de Gran Canaria Dr Negrín
(6)
Hospital Vall D'Hebrón de Barcelona
(7)
Hospital San Agustín
(8)
Hospital Universitario Dr Peset de Valencia
(9)
CIBER de Epidemiología y Salud Pública (CIBERESP)
(10)
CIBER de Enfermedades Respiratorias (CIBERES)

References

  1. TB: A Global Emergency WHO Report on the TB Epidemic. Geneva: WHO/TB/94.177;Google Scholar
  2. WHO Report 2009: Global tuberculosis control - epidemiology, strategy, financing. [http://www.who.int/tb/publications/global_report/en/index.html]
  3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: For the WHO Global Surveillance and Monitoring Project. Global Burden of Tuberculosis. Estimated Incidence, Prevalence, and Mortality by Country. JAMA 1999, 282:677–686.View ArticlePubMedGoogle Scholar
  4. INE: Series de población desde. [http://www.ine.es/jaxiBD/tabla.do] 1996.Google Scholar
  5. Orcau A, Rius C, Garcia de Olalla P, Caylà JA: Programa de Prevención y Control de la TB de Barcelona. Informe 2007. Barcelona: Publicaciones de la Agència de Salut Pública de Barcelona 2008.Google Scholar
  6. Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H, Working Group on Completion of Tuberculosis Treatment in Spain: Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis 2004, 8:458–64.PubMedGoogle Scholar
  7. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organisation (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998, 12:505–10.View ArticlePubMedGoogle Scholar
  8. Antoine D, French CE, Jones J, Watson JM: Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001. J Epidemiol Community Health 2007, 61:302–7.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Rodrigo T, Caylà JA, Galdós-Tangüis H, García de Olalla P, Brugal MT, Jansà JM: Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona. Int J Tuberc Lung Dis 2001, 5:432–40.PubMedGoogle Scholar
  10. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG: Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999, 3:273–80.PubMedGoogle Scholar
  11. Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL: Tuberculosis treatment outcomes. Am J Respir Crit Care Med 2004, 170:561–66.View ArticlePubMedGoogle Scholar
  12. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G: Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005, 7:5–14.Google Scholar
  13. Falzon D, Le Strat Y, Belghiti F, Infuso A, EuroTB Correspondents: Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tubec Lung Dis 2005, 9:1224–29.Google Scholar
  14. Kliiman K, Altraja A: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009, 33:1085–94.View ArticlePubMedGoogle Scholar
  15. Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fátima Duarte E: Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 2009, 63:233–238.View ArticlePubMedGoogle Scholar
  16. Lefebvre N, Falzon D: Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J 2008, 31:1256–60.View ArticlePubMedGoogle Scholar
  17. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE: Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34:752–9.View ArticlePubMedGoogle Scholar
  18. Bustamante-Montes LP, Escobar-Mesa A, Borja-Aburto VH, Gómez-Muñoz A, Becerra-Posada F: Predictors of death from pulmonary tuberculosis: the case of Veracruz, Mexico. Int J Tuberc Lung Dis 2000, 4:208–15.PubMedGoogle Scholar
  19. World Health Organization: Tuberculosis and migration. [http://www.euro.who.int/tuberculosis/publications/20071204_10]
  20. Grupo de Trabajo de los Talleres 2001 y 2002 de la Unidad de Investigación de Tuberculosis de Barcelona. Prevención y control de las tuberculosis importadas Med Clín (Barc) 2003, 121:549–62.Google Scholar
  21. Martin-Casabona N, Alcaide F, Coll P, González J, Manterola JM, Salvadó M, Caylà JA: Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 2000, 115:493–98.View ArticleGoogle Scholar
  22. Pérez del Molino Bernal ML, Túñez V, Cruz-Ferro E, Fernández-Villar A, Vázquez-Gallardo R, Díaz-Cabanela D, Anibarro L, Grupo Gale de Estudio de Resistencias de M. tuberculosis: Tuberculosis. Study of Mycobacterium tuberculosis drug reistance in the region of Galicia, Spain. Int J Tuberc Lung Dis 2005, 9:1230–35.PubMedGoogle Scholar
  23. Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez JA, García JM, Vidal R, Spanish Society of Pulmonology and Thoracic Surgery: Diagnosis and treatment of Tuberculosis. Recommendations of the Society of Pneumology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2008, 44:551–66.View ArticlePubMedGoogle Scholar
  24. American Thoracic Society and Centers Disease, Control and Prevention: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003, 167:603–66.View ArticleGoogle Scholar
  25. Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom. Thorax 1998, 53:536–48.View ArticleGoogle Scholar
  26. Grupo de Estudio del Taller de 1999 de la Unidad de Investigación de Tuberculosis de Barcelona: Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Med Clín (Barc) 2000, 115:749–57.View ArticleGoogle Scholar
  27. Marco A, Caylà JA, Serra M, Pedro R, Sanrama C, Guerrero R, Ribot N: Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998, 12:967–71.View ArticlePubMedGoogle Scholar
  28. Ospina JE, Orcau A, Millet JP, Caylà JA, Casals M, Rius C, Sánchez F, the Barcelona Tuberculosis and Immigration Working Group: Effectiveness of Community Health Workers for the control of tuberculosis. Abstract Book, 40 th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Int J Tuberc Lung Dis 2009,13(suppl 1):S186.Google Scholar

Copyright

© Caylà et al. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement